Omkar Pharmachem Intrinsic Value
Omkar Pharmachem (OMKARPH) median intrinsic value is ₹47.25 from 5 valuation models (range ₹37–₹47), vs current price ₹15.75 — +200.0% upside (Trading Below Calculated Value), margin of safety 66.7%. Read OMKARPH dividend growth for the complete payout history and dividend yield track record.
OMKARPH Valuation Methods Summary — DCF, Graham Number & P/E
Omkar Pharmachem intrinsic value across 5 models vs current price ₹15.75 — upside/downside and value range per method. Analyse OMKARPH promoter holding to track promoter, FII and institutional holdings.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹47.25 | ₹37.80 - ₹56.70 | +200.0% | EPS: ₹26.98, Sector P/E: 12x |
| Book Value Method | asset | ₹37.00 | ₹33.30 - ₹40.70 | +134.9% | Book Value/Share: ₹37.00, P/B: 1.0x |
| PEG Ratio Method | growth | ₹47.25 | ₹42.52 - ₹51.98 | +200.0% | EPS Growth: 20.0%, Fair P/E: 16.0x |
| Growth Adjusted P/E | growth | ₹47.25 | ₹42.52 - ₹51.98 | +200.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| Graham Defensive Method | conservative | ₹47.25 | ₹42.52 - ₹51.98 | +200.0% | EPS: ₹26.98, BVPS: ₹37.00 |
OMKARPH Intrinsic Value vs Market Price — All Valuation Models
Omkar Pharmachem fair value range ₹37–₹47 vs current market price ₹15.75 across 5 valuation models. For current market price and key ratios, visit Omkar Pharmachem stock price NSE.
OMKARPH Intrinsic Value Analysis — Undervalued or Overvalued?
Omkar Pharmachem median intrinsic value ₹47.25, current price ₹15.75 — Trading Below Calculated Value by 200.0%, margin of safety 66.7%.
What is the intrinsic value of OMKARPH?
Based on our comprehensive analysis using 5 different valuation methods, the estimated intrinsic value of Omkar Pharmachem (OMKARPH) is ₹47.25 (median value). With the current market price of ₹15.75, this represents a +200.0% variance from our estimated fair value.
The valuation range spans from ₹37.00 to ₹47.25, indicating ₹37.00 - ₹47.25.
Is OMKARPH undervalued or overvalued?
Based on our multi-method analysis, Omkar Pharmachem (OMKARPH) appears to be trading below calculated value by approximately 200.0%.
OMKARPH Cash Flow Quality — Operating & Free Cash Flow
Omkar Pharmachem operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2021 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |